Show simple item record

dc.contributor.authorVelpurisiva, Praveena
dc.contributor.authorPiel, Brandon
dc.contributor.authorLepine, Jack
dc.contributor.authorRai, Prakash
dc.date2022-08-11T08:08:16.000
dc.date.accessioned2022-08-23T15:48:35Z
dc.date.available2022-08-23T15:48:35Z
dc.date.issued2017-05-16
dc.date.submitted2017-07-02
dc.identifier.doi10.13028/1stz-fh74
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28241
dc.description.abstractGlioblastoma Multiforme (GBM) is an aggressive cancer that originates from astrocytes and spreads to spinal cord and other parts of the brain. Increase in replication of glial cells leads to advantageous mutations in the tumor. According to the cancer statistics from 2015 about 15,320 deaths were reported due to GBM. Five-year survival is less than 5% making GBM a dreadful form of cancer. Current treatment involves complex invasive surgery, followed by chemotherapy and radiation. The goal of this study is to develop a combination therapy to treat GBM using Poly (lactic-co-glycolic acid) (PLGA) nanoparticles encapsulated with two drugs namely gefitinib and GSK461364, each with a unique target. Gefitinib is a Tyrosine Kinase inhibitor, which competes for ATP-binding site of EGFR-TK. GSK461364 is a Polo-like Kinase (PLK-1) inhibitor that blocks the G2/M transition in tumor cell cycle. These distinct hydrophobic drugs are tested on U-87 MG (human malignant glioma) cell line. PLGA is attached to Polyethylene glycol (PEG), which is conjugated to transferrin receptor binding peptide. These transferrin peptides bind to transferrin receptors (TfR) or CD71 and enable the entry of PLGA-PEG nanoparticles across the Blood Brain Barrier (BBB). Results of characterization, TEM, SEM images, in vitro drug release profiles, stability, cytotoxicity assay, flow cytometry data of uptake of the nanoparticles will be presented.
dc.formatflash_audio
dc.language.isoen_US
dc.rightsCopyright the Author(s)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/
dc.subjectGlioblastoma Multiforme
dc.subjectcancer
dc.subjectnanoparticles
dc.subjectBiomedical Engineering and Bioengineering
dc.subjectChemical Engineering
dc.subjectNanomedicine
dc.subjectNanoscience and Nanotechnology
dc.subjectNeoplasms
dc.subjectTranslational Medical Research
dc.titlePolymeric Nanoparticles for Targeted Combination Treatment of Temozolomide Resistant Glioblastoma Multiforme (GBM)
dc.typePoster Abstract
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1580&context=cts_retreat&unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cts_retreat/2017/posters/85
dc.identifier.contextkey10386514
refterms.dateFOA2022-08-23T15:48:35Z
html.description.abstract<p>Glioblastoma Multiforme (GBM) is an aggressive cancer that originates from astrocytes and spreads to spinal cord and other parts of the brain. Increase in replication of glial cells leads to advantageous mutations in the tumor. According to the cancer statistics from 2015 about 15,320 deaths were reported due to GBM. Five-year survival is less than 5% making GBM a dreadful form of cancer. Current treatment involves complex invasive surgery, followed by chemotherapy and radiation. The goal of this study is to develop a combination therapy to treat GBM using Poly (lactic-co-glycolic acid) (PLGA) nanoparticles encapsulated with two drugs namely gefitinib and GSK461364, each with a unique target. Gefitinib is a Tyrosine Kinase inhibitor, which competes for ATP-binding site of EGFR-TK. GSK461364 is a Polo-like Kinase (PLK-1) inhibitor that blocks the G2/M transition in tumor cell cycle. These distinct hydrophobic drugs are tested on U-87 MG (human malignant glioma) cell line. PLGA is attached to Polyethylene glycol (PEG), which is conjugated to transferrin receptor binding peptide. These transferrin peptides bind to transferrin receptors (TfR) or CD71 and enable the entry of PLGA-PEG nanoparticles across the Blood Brain Barrier (BBB). Results of characterization, TEM, SEM images, <em>in vitro</em> drug release profiles, stability, cytotoxicity assay, flow cytometry data of uptake of the nanoparticles will be presented.</p>
dc.identifier.submissionpathcts_retreat/2017/posters/85


Files in this item

Thumbnail
Name:
84_Velpurisiva.docx
Size:
15.35Kb
Format:
Microsoft Word 2007
Thumbnail
Name:
auto_convert.pdf
Size:
14.18Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright the Author(s)
Except where otherwise noted, this item's license is described as Copyright the Author(s)